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ABSTRACT
Epidemiological studies indicated that fibrinogen and dyslipidemia were important risk factors for cardiovascular
disease (CVD). For several populations in the world, increase in cholesterol level and decrease in high-density lipoprotein
cholesterol (HDL-C) were risk factors for coronary heart disease (CHD). The role of elevated fibrinogen in thrombosis
suggests that it may be the causal pathway for certain risk factors of CHD. The aim of this study is to determine the
role of lipid profile and fibrinogen level as risk factors of coronary heart disease. Blood samples were obtained from
CHD patients, dyslipidemic patients, and controls after they had fasted. Lipid profiles and fibrinogen level of CHD
and dyslipidemic patients were determined and compared with controls. There were 92 subjects in this study,
consisted of 35 CHD patients, 31 dyslipidemic patients, and 26 controls. There were significant difference in
triglyceride level between CHD and dyslipidemic patients, also between dyslipidemic patients and controls (p<0.05).
Significant difference in level of cholesterol also existed between CHD patients and dyslipidemic patients, also
between CHD patients and controls (p < 0.05). In dyslipidemic patients, decreased in HDL-C level was risk factor
for CHD. Meanwhile for controls, high level of cholesterol and LDL-C also low level of HDL-C were risk factor for
CHD, but fibrinogen level was not risk factor for CHD. In conclusion, lipid profile was risk factor for CHD whereas
fibrinogen level was not risk factor for CHD.
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INTRODUCTION
Fibrinogen is one of the main parts of blood
plasma protein, and it strongly affects the
development of clot, rheological reaction, and platelet
aggregation. Fibrinogen also has impact on blood
vessel wall and is a strong acute phase reactant.
Increase in fibrinogen level was associated with the
increase risk of CHD stroke, myocardial infarction
(MI), and peripheral arterial diseases. 1-6 With
immuno-precipitation, fibrinogen showed strong
association with cardiovascular diseases, therefore
fibrinogen level might be used as screening tool to
identify the risk of thrombosis.7 Almost half of
coronary artery disease patients had higher
fibrinogen level compared with normal people.2,3,8-
10 Occlusive thrombi were found in most cases of
acute myocardial infarction, sudden death caused
by heart ischemia, and unstable angina. Thrombosis
is the main mechanism of atherosclerosis
complication.11-13 Atherosclerotic lesions, that will
form plaques, consist of extracellular hydrophobic
lipid accumulation, lipid-containing macrophages,
smooth muscle cells, and proteins in the endothelial
surface of artery. It was assumed that increasing
fibrinogen related with initial plaque formation,
caused by acute phase response.14-16 The association
of high fibrinogen level with pathogenesis of
atherosclerosis is supported by the fact that
fibrinogen induces disorganization and migration of
endothelial cells, stimulates smooth muscle cell
proliferation, and increases the release of growth
factors from endothelial cells.2
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Dyslipidemia, especially high cholesterol level,
is an indicator of liver function and increase risk of
CVD,17-19 whereas the role of triglyceride level as
risk factor of CHD is still controversial.20 The aim
of this study was to determine the role of fibrinogen
and lipid profile as risk factor of CHD.
MATERIALS AND METHODS
Subjects
This was a cross-sectional study. Subjects of
this study were CHD and dyslipidemic patients who
visited Dr. Sardjito Hospital Yogyakarta and were
obtained by consecutive random sampling. The
diagnosis of CHD was established by internist.
Dyslipidemic patients were patients with one
abnormality in the lipid level, while the elderly
aerobic group at Banteng village, Sleman district,
Yogyakarta were enrolled as control groups. The
protocol of this study was approved by the Health
Research Ethics Committee of Faculty of Medicine,
Gadjah Mada University, Yogyakarta.
Chemical analysis
Blood samples were obtained from the subjects
and controls after they had fasted. Plasma was
separated from the blood to determine lipid profiles
and fibrinogen level. To determine total cholesterol,
HDL-C, and triglyceride levels, plasma samples were
analyzed using Diaysis kit in Biochemistry
Laboratory, Department of Biochemistry, Faculty
of Medicine, Gadjah Mada University, Yogyakarta.
Low-density cholesterol level was determined using
Fridewald equation (1972). Fibrinogen level was
measured employing Fibrinoquik kit in Clinical
Pathology Laboratory, Dr. Sardjito Hospital,
Yogyakarta.
Data analysis
Group differences of continuous variables such
as lipid profiles and fibrinogen levels were compared
using Anova and t-test. Odd Ratio was calculated
using logistic regression analysis.
RESULTS
A total of 92 subjects which consisted of 35
CHD patients, 31 dyslipidemic patients and 26
controls were enrolled in this study. Data of age,
BMI (Body Mass Index), blood pressure, lipid profile
and fibrinogen levels of the subjects are shown in
TABLE 1 and FIGURE 1.
TABLE 1. Lipid profile and fibrinogen level of CHD patients, dyslipidemic patients, and controls (mean ± SD)
a Significant difference between CHD patients & dyslipidemic patients and also CHD patients and controls (p<0.05)
b Significant difference between CHD patients and dyslipidemic patients and also dyslipidemic patients & controls (p<0.05)
CHD patients
(n=35)
Dyslipidemic patients
(n=31)
Control
(n=26)
p
Male 23 12 15 >0.05
Female 12 19 11 >0.05
Age (years) 61.24±9.31 56.84±8.30 57.19±8.50 >0.05
BMI (kg/m2) 23.8±3.0 25.2±3.7 24.0±3.35 >0.05
Systolic BP (mmHg) 140.61±17.13 138.06±19.95 137.31±19.56 >0.05
Diastolic BP (mmHg) 83.94±10.29 87.10±9.57 89.04±12.96 >0.05
Cholesterol (mg/dL) 199.740±32.272a 154.490±66.470a 154.710±37.580a <0.05
HDL-C (mg/dL) 45.142±14.684 48.816±10.014 50.833±7.429 >0.05
LDL-C (mg/dL) 126.98±38.272 143.39±35.025 97.430±25.010 >0.05
Triglyceride (mg/dL) 132.900±71.069b 239.010±48.816b 117.560±51.476b <0.05
Fibrinogen (mg/dL) 291.20±90.38 315.38±79.31 349.330±70.33 >0.05
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FIGURE 1. Lipid and fibrinogen concentration in CHD, dyslipidemic patients and controls
Statistical analysis using Anova showed
significant differences (p<0.05) in total cholesterol
and triglyceride level between CHD patients,
dyslipidemic patients, and controls (TABLE 1).
Meanwhile t-test results showed there were
significant difference in triglyceride level between
CHD patients and controls also between dyslipidemic
patients and controls (p<0.05). Furthermore, there
were significant difference in cholesterol level
between CHD patients and dyslipidemic patients,
and also between CHD patients and controls
(p<0,05).
Odds ratio of lipid profile and fibrinogen
levels between CHD patients and controls were
shown in TABLE 2. This study observed that high
level of cholesterol and LDL-C also low HDL-C
level were high risk factor for CHD, but blood
pressure, triglyceride and fibrinogen level were not
risk factors (TABLE 2).
TABLE 2. Odd Ratio of lipid profile and fibrinogen levels between CHD patients and controls
CHD
N = 35
Controls
N = 26
OR
(CI 95%)
Systolic = 140 mmHg 20 (57%) 14 (54%) 1.14 (0.36-3.60 )
Diastolic = 90 mg/dL 13 (37%) 16 (61%) 0.37 (0.11-1.19)
Cholesterol > 200 mg/dL 15 (43%) 1 (4%) 14.77 (1.74 -327.02)
Triglyceride > 150 mg/dL 8 (23%) 7 (27%) 0.80 (0.21 -3.02)
HDL-C < 35 mg/dL 6 (17%) 1 (4%) 5.17 (0.54-121.93 )
LDL-C > 130 mg/dL 16 (46%) 4 (15%) 4.63 (1.16 -19.94)
Fibrinogen >350 mg/dL 8 (23%) 11 (54%) 0.40 (0.11 -1.40)
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DISCUSSION
A study by Benderly10 showed that high blood
pressure, both of systolic and diastolic blood
pressure, ware risk factor for CHD. However, this
study observed that blood pressure was not
significantly different between CHD patients and
controls. This indicated that blood pressure was not
risk factor for CHD. It was probably because that
CHD patients with high blood pressure usually
consume drugs to maintain their blood pressure.
Lipid profiles in this study were significantly different
between CHD patients, hyperlipidemic patients, and
control groups, in which cholesterol, triglyceride level
and dyslipidemia being the high risk factor for CHD.
Sgarbosa21 suggested that high cholesterol level
would accumulate in arterial wall and formed
atheroma plaque that would stimulate CHD.
Therefore, the higher HDL-C level the lower risk
of CHD. It was in contrast with LDL-C and
triglyceride levels, in which increase in LDL-C and
triglyceride levels tend to cause CHD.22 It was
understandable that in this study CHD patients had
showed lower HDL-C level than dyslipidemic
patients and controls, and higher cholesterol level
than controls. The pathophysiology of athero-
sclerosis is a complex interaction between cellular
compounds in atherosclerotic lesion.
Fibrin structure did not only depend on
fibrinogen level, but also on combination effect of
chemical and physical interactions in blood, including
LDL-C level, glucose level, and smoking.23
Fibrinogen was involved in subclinical phase of
coronary and extracoronary atherosclerosis, had
atherogenic effect in hyperlipidemia,3 and also
related to the incidence of peripheral occlusive arterial
diseases.24 High fibrinogen level is risk for
hypercoagulation that can obstruct the blood vessel,
and when it occurred in heart blood vessel, there
would be a risk of CHD development.4 However, it
was still not clear, because high fibrinogen level did
not obstruct blood vessel directly, except when there
was hyperthrombosis in heart blood vessels. Plasma
fibrinogen was an independent risk factor of CHD
in men, but its role was not clear in women.25,26
There were very few information on the
association between plasma fibrinogen level and
coronary heart diseases in Asia. Plasma fibrinogen
level in the Japanese was lower compared with the
normal plasma fibrinogen level of people in Western
countries. A study in Osaka showed that the mean
plasma fibrinogen level was 267 mg/dL.28 One mg/
dL increase in fibrinogen level was associated with
two times increased risk of death in 6 years. This
result showed that fibrinogen did not only involve
in pathogenesis of arterial disease, but also a strong
independent predictor of mortality. There was a
relationship between the increase in fibrinogen level
and the severity of atherosclerosis, supported by
data which suggested that local degradation of
plasma fibrin of more than 350 mg/dL was a strong
independent factor of brain and heart infarction.10
Infection might facilitate inflammation in
atherosclerotic process. The increase in fibrinogen
level in acute or chronic infection might increase
the risk of cardiovascular disorders.29 Patients with
renal transplant suffered chronic prothrombotic
reaction and persistent inflammation. The change
in fibrinogen level and factor VIIc in patients with
renal transplant was caused by the interaction
between genetic and environmental factors, and this
change supported the increased risk of cardiovascular
diseases.30 Obese patients also tended to have
increased fibrinogen levels.31 This study found that
controls had higher fibrinogen level than dyslipidemic
patients and CHD patients, but this was not
significantly different. Moreover, logistic regression
analysis showed that fibrinogen was not a risk factor
of CHD.
CONCLUSION
In this study, it was concluded that the change
in lipid profiles was risk factor of CHD, but it was
not the case for the change in plasma fibrinogen
level.
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